Private investors: FCPR

We apply our knowledge of French SMEs to help private investors who are looking for high-performance and meaningful investments

Private equity accessible to individual investors

  • Through its FCPR (“Fonds Communs de Placement à Risque”) range of private equity funds, Omnes Capital gives individual investors access to an asset class usually reserved for institutional investors.

Boost portfolio returns

  • Invest in unlisted SMEs that create wealth and employment
  • Diversify financial assets: recommended allocation for private equity - 5% of a portfolio
  • Achieve solid long-term performance: the class has outperformed the CAC 40 index by 5.2% over the past 10 years
  • Secure tax incentives: sales exempt from capital gains tax

Omnes’ expertise

  • 15 years’ experience
  • Rigorous selection of SMEs: high-performance French companies with a leadership position in their sector, genuine growth prospects, solid fundamentals and seasoned management team
  • Reasonable leverage and value creation underpinned by growth in portfolio companies net revenues
  • Strong entrepreneurial culture among management teams, who share the same vision as company executives
  • Direct access to the management team
  • Meetings with portfolio companies entrepreneurs and detailed reporting provided
Key figures
15
years’
experience
5
funds
dedicated to private investors
NewsRoom
Filters
Display:
Press release
11 April 2019
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance

NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance
Press release
09 April 2019
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Appointments within Omnes: Omnes welcomes five newcomers as Director, Principal, Analyst, Middle Office Managers, and promotes four Principals
Publication
Infrastructure Investor - Annual Review (March 2018)
II_AR-2017_v3.1.pdf
Press release
03 April 2019
AgomAb Therapeutics Completes Euros 21m Series A Financing
AgomAb Therapeutics Completes Euros 21m Series A Financing
Press release
19 March 2019
Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy

Omnes announces a 15% investor net IRR on its Capenergie 2 fund, focused on renewable energy
Press release
13 March 2019
Therapixel secures a €5 million Series A financing and strengthens its governance
Therapixel secures a €5 million Series A financing and strengthens its governance

Pages